Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to
Become Market Leaders as Praluent and Entresto Drive Revenue Growth is a
new market research publication announced by Reportstack. This report
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%.
The relative stagnation can be attributed to key product approvals coinciding with key patent expirations. Within cardiovascular disease there are a number of blockbuster products that have recently gone off-patent, and others are expected to in the coming years, many of which belong to key players.
"Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi's Praluent (alirocumab) is expected to help mitigate losses associated with falling revenues of its key products Lovenox (enoxaparin) and Plavix (clopidogrel).
To access full report with TOC, please visit Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth.
"Novartis' heart failure medicine Entresto was introduced to market in July 2015, and it was expected that its revenues to increase dramatically during the forecast period. Entresto is a combination medicine which has shown efficacy shown in clinical trials. Coupled with a high cost, which amounts to over $4,500 annually per patient, the medicine contributes to a very high revenue forecast of $5.7 billion by 2022."
"Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth" assesses the current clinical and commercial landscape through a comprehensive analysis of the innovation in the cardiovascular disease (CVD) market in the context of the overall pipeline. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals, with key indications such as hypertension, dyslipidemia and thrombotic events covered in detail. An understanding of the current treatment landscape is also provided, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the medicine mechanism of action.
Scope
A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
Identification
and assessment of key pipeline products, with a particular focus on
those due to be brought to market in the near future, as well as a sales
forecast for these products.
Identification of the leading
companies in the market, in terms of market share and growth. Company
analysis determines how dependent these companies are on CVD product
revenue. In addition, analysis determines the primary factors that will
drive market growth for the key companies.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%.
The relative stagnation can be attributed to key product approvals coinciding with key patent expirations. Within cardiovascular disease there are a number of blockbuster products that have recently gone off-patent, and others are expected to in the coming years, many of which belong to key players.
"Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi's Praluent (alirocumab) is expected to help mitigate losses associated with falling revenues of its key products Lovenox (enoxaparin) and Plavix (clopidogrel).
To access full report with TOC, please visit Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth.
"Novartis' heart failure medicine Entresto was introduced to market in July 2015, and it was expected that its revenues to increase dramatically during the forecast period. Entresto is a combination medicine which has shown efficacy shown in clinical trials. Coupled with a high cost, which amounts to over $4,500 annually per patient, the medicine contributes to a very high revenue forecast of $5.7 billion by 2022."
"Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth" assesses the current clinical and commercial landscape through a comprehensive analysis of the innovation in the cardiovascular disease (CVD) market in the context of the overall pipeline. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals, with key indications such as hypertension, dyslipidemia and thrombotic events covered in detail. An understanding of the current treatment landscape is also provided, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the medicine mechanism of action.
Scope
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment